Hepatitis B Treatment Showing Good Efficacy in Preclinical Trials
The combination of entecavir and birinapant eradicated the hepatitis B virus in preclinical trials.
The combination of entecavir and birinapant eradicated the hepatitis B virus in preclinical trials.
The FDA is warning healthcare providers about the risk for dosing errors with Zerbaxa (ceftolozane and tazobactam; Cubist) due to confusion of the strength displayed on the vial and carton labeling.
Ledipasvir and sofosbuvir with or without ribavirin is effective and safe for treating chronic genotype 1 hepatitis C virus infections.
Simeprevir and sofosbuvir had higher rates of SVR for patients with hepatitis C and compensated cirrhosis.
Treatment with inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) may reduce the risk of death from pneumonia and other causes although they are associated with an increased incidence of pneumonia.
The Food and Drug Administration (FDA) has approved Avelox (moxifloxacin; Bayer) for the treatment of pneumonic and septicemic plague, and for the prevention of plague in adults.
Researchers were shocked to discover that a medieval remedy for eye infections may be effective against up to 90 percent of methicillin-resistant Staphylococcus aureus (MRSA) infections.
Emergent BioSolutions announced that the Food and Drug Administration (FDA) has approved Anthrasil (anthrax immune globulin intravenous [human]), also known as AIGIV, for the treatment of inhalation anthrax in combination with appropriate antibacterial drugs.
An in vitro rapid blood assay has been shown to differentiate between bacterial and viral infections with significant sensitivity and specificity, outperforming routine biomarker and laboratory tests.
New evidence has emerged exploring the relationship between gut microbiome, autism spectrum disorder (ASD), and probiotic treatment.